📋 Tender Overview
Advancing The Clinical Development Of Placental Malaria Vaccines In The Context Of Capacity Building And Use Of Digital Health Technologies
Accelerating Research For Placental Malaria Vaccinesplacental Malaria (Pm) Is A Life-Threatening Disease. Pregnant Women And Babies Are Particularly Vulnerable. The Eu-Funded Advance-Vac4Pm Project Aims To Accelerate The Development Of A Pm Vaccine By Obtaining Optimal Cross-Reactivity Of Two Promising Vaccine Candidates – Pamvac And Primvac – That Have Successfully Passed Phase I Clinical Studies In Europe And Africa. Researchers Will Leverage A Novel Vaccine Platform Based On Capsid Virus-Like Particles And Will Evaluate The Co-Administration Of The Two Vaccines To Enhance Immune Response. The Project Will Also Involve Training And Community-Based Research At The African Institutions To Assess Mobile Applications For Monitoring Pregnancy Outcomes And To Model The Development And Commercialisation Of Pm Vaccines.
Funded Under
Health
Total Cost
€ 9 999 995,00
Eu Contribution
€ 9 999 995,00
Coordinated By
European Vaccine Initiative E.V
Germany
Start Date
1 June 2022
End Date
31 May 2027